Aspirin for primary prevention of CVD: Are the right people using it?

Journal of Family Practice

Volumn 61, Issue 9, 2012, Pages 525-532

  VanWormer, Jeffrey J ^a   Greenlee, Robert T ^a   McBride, Patrick E ^b   Peppard, Paul E ^b   Malecki, Kristen C ^b   Che, Jianhong ^b   Nieto, F Javier ^b  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG INDICATION; FEMALE; HISPANIC; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; SOCIAL ASPECT; UNITED STATES; AGE; ETHNIC GROUP; ETHNOLOGY; HEALTH SURVEY; MEDICATION COMPLIANCE; METHODOLOGY; MIDDLE AGED; POPULATION DYNAMICS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICS;

ADULT; AGE FACTORS; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; ETHNIC GROUPS; FEMALE; HEALTH SURVEYS; HEALTH TRANSITION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; WISCONSIN;

EID: 84878241212     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. .Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
3. Sullivan PW, Ghushchyan V, Wyatt HR,et al. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity. 2007;15:3150-3158. (Pubitemid 351256679)
4. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391. (Pubitemid 34778969)
5. Kriekard P, Gharacholou SM, Peterson ED. Primary and secondary prevention of cardiovascular disease in older adults: a status report. Clin Geriatr Med. 2009;25:745-755.
6. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398. (Pubitemid 46883773)
7. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6:95-107.
8. Barnett H, Burrill P, Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. BMJ. 2010;340:c1805.
9. Sanchez-Ross M, Waller AH, Maher J, et al. Aspirin for the prevention of cardiovascular morbidity. Minerva Med. 2010;101:205-214.
10. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement. Ann Intern Med. 2009;150:396-404.
11. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796-1801.
12. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52-61. (Pubitemid 43956597)
13. Pignone M, Anderson GK, Binns K, et al. Aspirin use among adults aged 40 and older in the United States results of a national survey. Am J Prev Med. 2007;32:403-407.
14. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among US adults: behavioral risk factor surveillance system. Am J Prev Med. 2006;30:74-77. (Pubitemid 43083548)
15. Sanchez DR, Diez Roux AV, Michos ED, et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol. 2011;107:41-46.
16. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2:e353.
17. Rodondi N, Vittinghoff E, Cornuz J, et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med. 2005;118(suppl):1288e1-1288e9.
18. Rodondi N, Cornuz J, Marques-Vidal P, et al. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med. 2008;46:137-144. (Pubitemid 351163307)
19. Nieto FJ, Peppard PE, Engelman CD, et al. The Survey of the Health of Wisconsin (SHOW), a novel infrastructure for population health research: rationale and methods. BMC Public Health. 2010;10:785.
20. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753. (Pubitemid 351640675)
21. Cody RP, Smith JK. Applied Statistics and the SAS Programming Language. New York, NY: Prentice Hall; 2005.
22. Mallonee S, Daniels CG, Mold JW, et al. Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma. J Okla State Med Assoc. 2010;103:254-260.
23. Centers for Disease Control and Prevention (CDC). Prevalence of aspirin use to prevent heart disease-Wisconsin, 1991, and Michigan, 1994. MMWR Morb Mortal Wkly Rep. 1997;46:498-502.
24. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-160.
25. Werner M, Kelsberg G, Weismantel AM. Which healthy adults should take aspirin? J Fam Pract. 2004;53:146-150. (Pubitemid 38176595)
26. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.
27. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-638. (Pubitemid 44128438)
28. VanWormer JJ, Johnson PJ, Pereira RF, et al. The Heart of New Ulm project: using community-based cardiometabolic risk factor screenings in a rural population health improvement initiative. Popul Health Manag. 2012;15:135-143.
29. Jeffreys D. Aspirin: The Remarkable Story of a Wonder Drug. New York, NY: Bloomsbury Publishing; 2005.
30. Smith NL, Psaty BM, Heckbert SR, et al. The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly. J Clin Epidemiol. 1999;52:143-146. (Pubitemid 29118364)
31. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717-722. (Pubitemid 29401332)